Brief: Intelligent Bio Solutions Concludes In-Clinic Testing For Clinical Study Plan
27/09/2024 13:34
Sept 27 (Reuters) - Intelligent Bio Solutions Inc
INBS.O :
* INTELLIGENT BIO SOLUTIONS CONCLUDES IN-CLINIC TESTING FOR
CLINICAL STUDY PLAN, ADVANCING TOWARD FDA 510(K) SUBMISSION
* INTELLIGENT BIO SOLUTIONS INC - EXPECTS TO SUBMIT 510(K)
PACKAGE
IN Q4 2024
Source text for Eikon: ID:nGNX7LKYPL
Further company coverage: INBS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelligent Bio Solutions
See all newsBrief: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%
Intelligent Bio Solutions rise after clearing security tests ahead of FDA filing
Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study